alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic
February 1996
The FDA is alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic.
They're requiring new info in the package insert...and having manufacturers send out a letter to prescribers.
This concern is based on toxicology studies which show an increased incidence of liver tumors in some mice...but not in rats.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote